A cell surface receptor called Programmed Death-1 (PD-1) serves as a T cell checkpoint and is crucial in controlling T cell exhaustion. PDL-1 or PDL-2 engagement with PD-1 causes it to become active. When the PD-1 receptor binds to its ligands, PD-L1 and PD-L2, which are expressed on cancer cells and antigen-presenting cells, it sends inhibitory checkpoint signals to activated T cells. This suppresses T-cell effector function and allows tumor immune evasion. An appealing approach for tumor immunotherapy is to block the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway.
Activated T cells, B cells, monocytes, dendritic cells, regulatory T cells, and natural killer T cells all express PD-1. It belongs to a group of immunoglobulin domain (Ig) co-receptors that affect how the T cell receptor responds when activated by an antigen-presenting cell (APC) or an infected target cell. In contrast to PD-L2, which is only and inducibly expressed on professional APCs, PD-L1 is widely expressed and constitutively on both hematopoietic and nonhematopoietic cells, including naive T and B cells, vascular endothelial cells, and pancreatic islet cells.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V75249 | (D)-PPA 1 | 1620813-53-7 | (D)-PPA 1 is a hydrolytic D-peptide antagonist. |
|
V75209 | Acasunlimab (GEN1046) | 2253937-12-9 | Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. |
|
V75219 | Acrixolimab | 2506324-29-2 | Acrixolimab is a human IgG4-κ antibody targeting PD-1. |
|
V75245 | ASC-69 (APY69) | 1216665-50-7 | ASC-69 (APY69) is a potent small molecule inhibitor of PD-1/PD-L1. |
|
V75244 | Atorolimumab (P3x22914G4) | 202833-08-7 | Atorolimumab (P3x22914G4) is a monoclonal antibody (mAb) used in immunotherapy targeting programmed death-1 (PD-1). |
|
V75223 | Balstilimab (AGEN2034) | 2148321-77-9 | Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody directed against PD-1. |
|
V74276 | Benmelstobart | 2303884-58-2 | Benmelstobart is an IgG1κ antibody targeting PD-L1/CD274, developed from mice. |
|
V74270 | Betifisolimab (MSB-2311) | 2460539-60-8 | Betifisolimab (MSB-2311) is a humanized monoclonal antibody (mAb) directed against the immunosuppressive ligand PD-L1. |
|
V2191 | BMS-1001 Sodium salt | 1380650-53-2 | BMS-1001 is a novel and potent PD-1/PD-L1 interaction inhibitor. |
|
V3826 | BMS-1166 HCl | 2113650-05-6 | BMS-1166 HCl, the hydrochloride salt ofBMS1166, is a novel and potent small molecule inhibitor of the PD-1/PD-L1 PPI/protein protein interaction with anticancer and immunomodulatory activity. |
|
V75251 | BMSpep-57 | 1629655-80-6 | BMSpep-57 is a potent macrocyclic peptide inhibitor that can suppress PD-1/PD-L1 interaction with IC50 of 7.68 nM. |
|
V75215 | Budigalimab (ABBV 181; PR 1648817) | 2098225-93-3 | Budigalimab (ABBV 181; PR 1648817) is a human IgG1 monoclonal antibody (mAb) targeting the programmed cell death 1 (PD-1) receptor. |
|
V3254 | CA-170 | 1673534-76-3 | CA-170 (also known as AUPM170 or PD-1-IN-1) is a first-in-class, potent and orally available small molecule inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1), PD-L2 and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation (programmed death 1 homolog; PD-1H). |
|
V75199 | Camrelizumab (Camrelizumab; SHR-1210) | 1798286-48-2 | Camrelizumab (SHR-1210) is a humanized IgG4-κ anti-PD-1 monoclonal antibody (mAb). |
|
V75205 | Cemiplimab | 1801342-60-8 | Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T cell suppression. |
|
V75214 | Cosibelimab (CK-301; TG-1501) | 2216751-26-5 | Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1 blocking monoclonal antibody (mAb) that binds to PD-L1 and blocks its interaction with PD-1. |
|
V74273 | Danburstotug (dabusutalumab; IMC-001; STI-3031) | 2307144-65-4 | Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (programmed cell death 1 ligand 1, PDL1, B7 homolog 1, B7H1) humanized monoclonal antibody (mAb). |
|
V75203 | Dostarlimab (TSR-042) | 2022215-59-2 | Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody (mAb). |
|
V74275 | Eciskafusp alfa | 2649758-52-9 | Eciskafusp alfa is a programmed cell death 1 (PDCD1, best known as PD-1) cis-targeting IL2v immune cytokine. |
|
V3348 | Evixapodlin | 2374856-75-2 | Evixapodlin (GS-4224) is an inhibitor (blocker/antagonist) of human PD-1/PD-L1 protein/protein interaction with IC50 of 0.213 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
